Recon: FDA approves Journey’s rosacea drug; EU to decide on Novo’s Catalent acquisition by 6 December
ReconJason Scott
Approval/marketing authorizationBiologics/ biosimilars/ vaccinesEuropeEuropean CommissionGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)